Latest Headlines

Latest Headlines

Pfizer armed and ready for Lipitor fight

Pfizer isn't letting Lipitor go gently into the good night of off-patent drugs. It's fighting to keep the cholesterol remedy's sales up until the bitter end. That's a tough assignment, given that

AZ's Crestor flubs key heart failure trial

AstraZeneca didn't get its coveted results from the long-awaited CORONA trial. Crestor failed to show any statistically significant benefit in heart failure patients. So Crestor lacks a competitive

Pfizer judge won't toss'biased' evidence

Pfizer used an old legal strategy in defending its Nigerian trial of an experimental meningitis drug: Discredit the witness. One key piece of evidence against the drug giant is a government report

Pfizer-Sanofi match not made in heaven?

Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost

Merck cautiously upbeat on cholesterol drug

Merck is looking to succeed where Pfizer so spectacularly failed. Merck presented positive Phase II data for its CTEP inhibitor

Court: Pfizer can defend Neurontin patent

Pfizer will get its day in court with Neurontin--and its chance to collect at-risk damages from generics companies that pounced on the drug. A federal appeals court overturned portions of a 2005

Generics beat down drug price inflation

Generics may be the bane of Big Pharma, but they're inflation-fighting ninjas. Over the last 12 months, prescription drug prices edged up by a measly 1 percent--the lowest rate of inflation in three

Pfizer honcho details plans to boost sales

Pfizer's drug chief opened up his playbook yesterday at a San Francisco investment conference. Ian Read, president of worldwide pharmaceutical operations, confided worries about its top seller,

ALSO NOTED: Bayer drug moves up to first-line leukemia treatment; St. Jude Medical adding 1,200 jobs in Puerto Rico

> Bayer got the FDA's blessing to market its Campath leukemia drug as a first-line treatment against the disease; previously, Campath was only approved for use when other therapies had failed.

Pfizer's future rests with biotech

At this week’s Bear Stearns Healthcare Conference, Pfizer discussed its plans for the future with analysts. As we all know, Pfizer is facing a major loss of sales when its best-selling drug